| Gantenerumab Reduces Brain Amyloid in Alzheimer's |
| Tuesday, 11 October 2011 |
| Treatment with gantenerumab, an anti–amyloid-β monoclonal antibody, resulted in a dose-dependent reduction in brain amyloid in patients with mild to moderate Alzheimer's disease (AD), a small trial shows. However, "no consistent treatment effects on cognitive measures were noted in this small group of patients treated for a short period of time," wrote lead author Susanne Ostrowitzki, MD, who works in the Department of Neuroscience at F. Hoffmann-La Roche Ltd. — the drug’s manufacturer — in Basel, Switzerland. |
|
อ่านรายละเอียดเพิ่มเติม...
|
